Spyglass Capital Management LLC Sells 152,574 Shares of Ascendis Pharma A/S $ASND

Spyglass Capital Management LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 41.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 215,398 shares of the biotechnology company’s stock after selling 152,574 shares during the quarter. Ascendis Pharma A/S makes up approximately 3.1% of Spyglass Capital Management LLC’s investment portfolio, making the stock its 20th largest position. Spyglass Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $57,451,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ASND. Advisory Services Network LLC bought a new stake in Ascendis Pharma A/S in the third quarter valued at approximately $26,000. Arax Advisory Partners boosted its stake in shares of Ascendis Pharma A/S by 212.2% during the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 104 shares during the period. Leonteq Securities AG bought a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $42,000. Finally, Global Retirement Partners LLC increased its holdings in shares of Ascendis Pharma A/S by 111.9% during the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 113 shares during the last quarter.

Ascendis Pharma A/S Trading Up 6.1%

ASND opened at $263.04 on Tuesday. Ascendis Pharma A/S has a twelve month low of $186.05 and a twelve month high of $282.15. The company has a 50-day simple moving average of $256.44 and a 200 day simple moving average of $239.47. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $16.41 billion, a price-to-earnings ratio of 20.41 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Analysts predict that Ascendis Pharma A/S will post 3.9 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 2,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was purchased at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the purchase, the director directly owned 2,900 shares of the company’s stock, valued at approximately $714,357. This trade represents a 222.22% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 40.00% of the stock is owned by insiders.

Analysts Set New Price Targets

ASND has been the subject of several research reports. Weiss Ratings raised Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Oppenheimer reaffirmed an “outperform” rating on shares of Ascendis Pharma A/S in a research report on Tuesday, June 9th. UBS Group set a $345.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday. Morgan Stanley raised their target price on shares of Ascendis Pharma A/S from $256.00 to $275.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Citigroup started coverage on shares of Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $304.95.

Trending Headlines about Ascendis Pharma A/S

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Ascendis Pharma entered a binding term sheet with BioMarin Pharmaceutical for a global settlement and license agreement related to YUVIWEL (navepegritide). The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty and potentially improving the commercial outlook for the product. The market reacted favorably, with shares rising after the announcement. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL
• Positive Sentiment: Analysts continue to rate ASND positively. HC Wainwright maintained a Buy rating and a $345 price target, while Bank of America retained its Buy rating with a $304 target, both implying upside from the stock’s referenced $263.04 level. The stock also received an average Buy rating from covering analysts. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Neutral Sentiment: Bank of America trimmed its price target modestly from $306 to $304 while keeping a Buy rating, signaling slightly reduced valuation expectations but continued confidence in Ascendis Pharma’s prospects.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for every reported period from the third quarter of 2026 through the fourth quarter of 2027. Its FY2027 estimate fell to $11.25 from $11.88, while quarterly estimates were reduced by $0.07 to $0.19. These revisions indicate that the analyst expects somewhat slower near-term earnings growth, despite maintaining the Buy rating and $345 target.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.